L-GLUTAMINE Drug Patent Profile
✉ Email this page to a colleague
When do L-glutamine patents expire, and when can generic versions of L-glutamine launch?
L-glutamine is a drug marketed by Annora Pharma, Novitium Pharma, and Renova Pharms. and is included in three NDAs.
The generic ingredient in L-GLUTAMINE is l-glutamine. There is one drug master file entry for this compound. Four suppliers are listed for this compound. Additional details are available on the l-glutamine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for L-glutamine
A generic version of L-GLUTAMINE was approved as l-glutamine by NOVITIUM PHARMA on July 8th, 2024.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for L-GLUTAMINE?
- What are the global sales for L-GLUTAMINE?
- What is Average Wholesale Price for L-GLUTAMINE?
Summary for L-GLUTAMINE
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 3 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 188 |
| Clinical Trials: | 196 |
| DailyMed Link: | L-GLUTAMINE at DailyMed |
Recent Clinical Trials for L-GLUTAMINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| NYU Langone Health | PHASE2 |
| Chan, Stephen, MD, PhD | PHASE1 |
| Synhale Theraputics | PHASE1 |
Pharmacology for L-GLUTAMINE
| Drug Class | Amino Acid |
US Patents and Regulatory Information for L-GLUTAMINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annora Pharma | L-GLUTAMINE | l-glutamine | FOR SOLUTION;ORAL | 219722-001 | May 26, 2026 | AA | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Novitium Pharma | L-GLUTAMINE | l-glutamine | FOR SOLUTION;ORAL | 215647-001 | Jul 8, 2024 | AA | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Renova Pharms | L-GLUTAMINE | l-glutamine | FOR SOLUTION;ORAL | 219750-001 | May 14, 2026 | AA | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
